Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZK 304709 |
Synonyms | |
Therapy Description |
ZK 304709 is a small molecule kinase inhibitor of CDKs 1, 2, 4, 7, and 9, VEGFR-1,2,3, and PDGFR-beta, which may result in inhibition of both the cell cycle and angiogenesis (PMID: 18653327, PMID: 19280191). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZK 304709 | CDK1 Inhibitor 13 CDK2 Inhibitor 31 CDK4 Inhibitor 17 CDK7 Inhibitor 16 CDK9 Inhibitor 21 PDGFR-beta Inhibitor 14 VEGFR Inhibitor (Pan) 36 | ZK 304709 is a small molecule kinase inhibitor of CDKs 1, 2, 4, 7, and 9, VEGFR-1,2,3, and PDGFR-beta, which may result in inhibition of both the cell cycle and angiogenesis (PMID: 18653327, PMID: 19280191). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A loss | neuroendocrine tumor | sensitive | ZK 304709 | Preclinical | Actionable | In a preclinical study, an orthotopic mouse model treated with ZK 304709 demonstrated an 80% tumor growth reduction in neuroendocrine tumor cells with CDKN2A loss (PMID: 18829975). | 18829975 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|